DIM
CCCC icon

Delta Investment Management’s C4 Therapeutics CCCC Stock Holding History

Delta Investment Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$38.2K – 280
2025
Q4 		$38.2K Buy
+20,000
New +$47.4K 0.01% 278
2025
Q2 		– Sell
-20,000
Closed -$32K – 242
2025
Q1 		$32K Hold
20,000
– – 0.01% 237
2024
Q4 		$72K Buy
+20,000
New +$99.4K 0.01% 252

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Delta Investment Management's CCCC Position: Q1 2026 in Review

Delta Investment Management sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 20,000 shares — an estimated $38.2K sold.

Delta Investment Management first reported a position in CCCC in Q4 2024 and held it in 3 quarters. The position peaked at $72K in Q4 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Delta Investment Management reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Delta Investment Management sold 20,000 C4 Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Delta Investment Management first reported a position in C4 Therapeutics in Q4 2024 and held it in 3 quarters.
  • Delta Investment Management's C4 Therapeutics position peaked at $72K in Q4 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Delta Investment Management's 13F filing for Q1 2026, filed 13 May 2026.